{"url_path":"/sec/bglc/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1737523/0001477932-26-003242-index.html","accession_number":"0001477932-26-003242","cik":"0001737523","ticker":"BGLC","issuer_name":"BioNexus Gene Lab Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/1737523/0001477932-26-003242-index.html","primary_entity_key":"0001737523","primary_entity_name":"BioNexus Gene Lab Corp"},"word_count":969,"has_tables":true,"body_markdown":"bglc_10q.htm\n0001737523false--12-31Q120260000000falsefalsefalsefalseP12M0000.10.1241731400017375232026-01-012026-03-310001737523bglc:FiveFormerOfficersAndDirectorsMemberus-gaap:SubsequentEventMember2026-05-032026-05-130001737523bglc:TwoThousandTwentyFiveEquityIncentivePlanMember2025-11-200001737523bglc:PurchaseAgreementMember2025-11-012025-11-280001737523bglc:InvestmentHoldingMember2025-01-012025-12-310001737523bglc:TradingOfIndustrialChemicalsMember2025-01-012025-12-310001737523bglc:ProvisionForGenomicScreeningServicesMember2025-01-012025-12-310001737523bglc:InvestmentHoldingMember2026-01-012026-03-310001737523bglc:InvestmentHoldingMember2025-01-012025-03-310001737523bglc:ProvisionForGenomicScreeningServicesMember2026-01-012026-03-310001737523bglc:ProvisionForGenomicScreeningServicesMember2025-01-012025-03-310001737523bglc:ATMProgramMemberbglc:FormS3Member2025-11-012025-11-070001737523bglc:ATMProgramMemberbglc:FormS3Member2025-11-070001737523bglc:ARCGroupInternationLtdMember2025-11-012025-11-300001737523bglc:FidelionDiagnosticsPteLtdMember2025-11-300001737523bglc:ARCGroupInternationLtdMember2025-11-3000017375232025-03-282025-04-0200017375232025-03-012025-03-190001737523bglc:MajorCustomerMember2026-01-012026-03-310001737523bglc:MajorsuppliersMember2026-01-012026-03-310001737523bglc:MajorCustomerMember2025-01-012025-03-310001737523bglc:MajorsuppliersMember2025-01-012025-03-310001737523bglc:VendorBMember2026-01-012026-03-310001737523bglc:VendorAMember2026-01-012026-03-310001737523bglc:VendorBMember2025-01-012025-03-310001737523bglc:VendorAMember2025-01-012025-03-310001737523country:LK2026-01-012026-03-310001737523country:LK2025-01-012025-03-310001737523country:SG2026-01-012026-03-310001737523country:SG2025-01-012025-03-310001737523country:MV2026-01-012026-03-310001737523country:MV2025-01-012025-03-310001737523bglc:BAMMember2026-01-012026-03-310001737523bglc:BAMMember2025-01-012025-03-310001737523bglc:ScreeningServicesAndRelatedSalesMember2026-01-012026-03-310001737523bglc:ScreeningServicesAndRelatedSalesMember2025-01-012025-03-310001737523bglc:TradingOfIndustrialChemicalsMember2026-01-012026-03-310001737523bglc:TradingOfIndustrialChemicalsMember2025-01-012025-03-310001737523bglc:FidelionMember2026-03-310001737523bglc:FidelionDiagnosticsPteLtdMember2026-01-012026-03-310001737523country:SG2026-03-310001737523country:SG2025-12-310001737523bglc:MachineryMember2025-12-310001737523bglc:SolarPVSystemMember2025-12-310001737523bglc:SignboardMember2025-12-310001737523bglc:RenovationMember2025-12-310001737523us-gaap:OfficeEquipmentMember2025-12-310001737523bglc:MotorVehicleMember2025-12-310001737523bglc:LandAndBuildingsMember2026-03-310001737523bglc:LandAndBuildingsMember2025-12-310001737523bglc:LabEquipmentMember2025-12-310001737523bglc:FurnitureAndFittingsMember2025-12-310001737523us-gaap:EquipmentMember2025-12-310001737523bglc:ComputerAndSoftwareMember2025-12-310001737523bglc:AirconditionerMember2025-12-310001737523bglc:FinanceLeaseLiabilityMember2025-12-310001737523bglc:FinanceLeaseLiabilityMember2026-03-310001737523bglc:MalayanBankingMember2026-01-012026-03-310001737523bglc:OperatingLeaseLiabilityMember2026-03-310001737523bglc:OperatingLeaseLiabilityMember2026-01-012026-03-310001737523bglc:OperatingLeaseLiabilityMember2025-01-012025-12-310001737523bglc:OperatingLeaseLiabilityMember2025-12-310001737523bglc:OperatingLeaseLiabilityMember2024-12-310001737523country:MA2026-03-310001737523country:US2025-03-310001737523country:US2026-01-012026-03-310001737523country:MA2026-01-012026-03-310001737523country:MA2025-03-310001737523country:US2026-03-310001737523country:US2025-12-310001737523country:MY2026-03-310001737523country:MY2025-12-310001737523bglc:FederalMember2025-01-012025-03-310001737523bglc:FederalMember2026-01-012026-03-310001737523country:MY2025-01-012025-03-310001737523bglc:LocalMember2025-01-012025-03-310001737523country:MY2026-01-012026-03-310001737523bglc:LocalMember2026-01-012026-03-3100017375232025-11-2800017375232025-11-012025-11-280001737523bglc:OneCustomerMember2023-07-012026-03-310001737523bglc:OneCustomerMember2021-05-012023-06-3000017375232025-01-012025-12-310001737523bglc:SignboardMember2026-03-310001737523bglc:RenovationMember2026-03-310001737523us-gaap:OfficeEquipmentMember2026-03-310001737523bglc:MotorVehicleMember2026-03-310001737523bglc:LabEquipmentMember2026-03-310001737523bglc:FurnitureAndFittingsMember2026-03-310001737523us-gaap:EquipmentMember2026-03-310001737523bglc:ComputerAndSoftwareMember2026-03-310001737523bglc:SolarPVSystemMember2026-03-310001737523bglc:MachineryMember2026-03-310001737523bglc:BuildingsMember2026-03-310001737523bglc:AirconditionerMember2026-03-310001737523bglc:ChemrexCorporationSdnBhdMember2026-01-012026-03-310001737523bglc:BGSLabSdnBhdMember2026-01-012026-03-310001737523us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-310001737523us-gaap:RetainedEarningsMember2026-03-310001737523us-gaap:AdditionalPaidInCapitalMember2026-03-310001737523us-gaap:CommonStockMember2026-03-310001737523us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-310001737523us-gaap:RetainedEarningsMember2026-01-012026-03-310001737523us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001737523us-gaap:CommonStockMember2026-01-012026-03-310001737523us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310001737523us-gaap:RetainedEarningsMember2025-12-310001737523us-gaap:AdditionalPaidInCapitalMember2025-12-310001737523us-gaap:CommonStockMember2025-12-3100017375232025-03-310001737523us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310001737523us-gaap:RetainedEarningsMember2025-03-310001737523us-gaap:AdditionalPaidInCapitalMember2025-03-310001737523us-gaap:CommonStockMember2025-03-310001737523us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310001737523us-gaap:RetainedEarningsMember2025-01-012025-03-310001737523us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001737523us-gaap:CommonStockMember2025-01-012025-03-3100017375232024-12-310001737523us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001737523us-gaap:RetainedEarningsMember2024-12-310001737523us-gaap:AdditionalPaidInCapitalMember2024-12-310001737523us-gaap:CommonStockMember2024-12-3100017375232025-01-012025-03-3100017375232026-03-3100017375232025-12-3100017375232026-05-15iso4217:USDxbrli:sharesiso4217:USDxbrli:sharesxbrli:purebglc:integer\n\n \n\n**UNITED STATES** \n\n**SECURITIES AND EXCHANGE COMMISSION** \n\n**WASHINGTON, DC 20549**\n\n \n\n**FORM 10-Q** \n\n \n\n☒\n\nQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\n \n\nFor the quarterly period ended **March 31, 2026**\n\n \n\nOR\n\n \n\n☐\n\nTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\n \n\nFor the transition period from _____________\n\n \n\nCommission File Number: **001-41750**\n\n \n\n**BioNexus Gene Lab Corp.**\n\n(Exact name of registrant as specified in its charter)\n\n \n\n**Wyoming**\n\n**35-2604830**\n\n(State or Other Jurisdiction of\n\n \n\n(I.R.S. Employer\n\nIncorporation or Organization)\n\n \n\nIdentification No.)\n\n \n\n \n\n**Unit A-28-7, Level 28, Tower A,**\n\n**Menara UOA Bangsar,**\n\n**No.5 Jln Bangsar Utama 1,**\n\n**Kuala Lumpur, Malaysia**\n\n**59000**\n\n(Address of Principal Executive Offices)\n\n \n\n(Zip Code)\n\n \n\n**+1 307 241 6898**\n\n(Registrant’s telephone number, including area code)\n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\n**Title of each class**\n\n \n\n**Trading Symbol(s)**\n\n \n\n**Name of each exchange on which registered**\n\nCommon stock, no par value\n\n \n\nBGLC\n\n \n\nThe Nasdaq Stock Market LLC\n\n \n\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒     No ☐\n\n \n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒     No ☐\n\n \n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer, “ “ accelerated filer, “ “non-accelerated filer ,” “ smaller reporting company, “ and “ emerging growth company “ in Rule 12b-2 of the Exchange Act. (Check one):\n\n \n\nLarge accelerated filer\n\n☐\n\nAccelerated filer\n\n☐\n\nNon-accelerated Filer\n\n☒\n\nSmaller reporting company\n\n☒\n\n \n\n \n\nEmerging growth company\n\n☒\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐    No ☒\n\n \n\nAs of May 15, 2026, there were 2,417,314 shares of common stock, no par value per share, issued and outstanding.\n\n \n\n \n\n \n\n \n\n**TABLE OF CONTENTS**\n\n \n\n[PART I – FINANCIAL INFORMATION](#p1)\n\n \n\n**Page**\n\n \n\n[Item 1.](#i1)\n\n[Financial Statements](#i1)\n\n \n\n4\n\n \n\n[Item 2.](#i2)\n\n[Management’s Discussion and Analysis of Financial Condition and Results of Operations](#i2)\n\n \n\n31\n\n[Item 3.](#i3)\n\n[Quantitative and Qualitative Disclosures About Market Risk](#i3)\n\n \n\n40\n\n[Item 4.](#i4)\n\n[Controls and Procedures](#i4)\n\n \n\n41\n\n \n\n \n\n \n\n \n\n \n\n \n\n[PART II – OTHER INFORMATION](#p2)\n\n \n\n \n\n \n\n \n\n \n\n \n\n[Item 1.](#p2i1)\n\n[Legal Proceedings](#p2i1)\n\n \n\n42\n\n[Item 1A.](#p2i1a)\n\n[Risk Factors](#p2i1a)\n\n \n\n42\n\n \n\n[Item 2.](#p2i2)\n\n[Unregistered Sale of Equity Securities and Use of Proceeds](#p2i2)\n\n \n\n43\n\n[Item 3.](#p2i3)\n\n[Defaults Upon Senior Securities](#p2i3)\n\n \n\n43\n\n[Item 4.](#p2i4)\n\n[Mine Safety Disclosures](#p2i4)\n\n \n\n43\n\n[Item 5.](#p2i5)\n\n[Other Information](#p2i5)\n\n \n\n43\n\n[Item 6.](#i6)\n\n[Exhibits](#i6)\n\n \n\n44\n\n \n\n**SIGNATURES**\n\n \n\n45\n\n \n\n \n\n2\n\n*Table of Contents*\n\n \n\n**CAUTIONARY NOTE REGARDING**\n\n \n\n**FORWARD-LOOKING STATEMENTS**\n\n \n\nThis Quarterly Report on Form 10-Q contains statements that may be deemed to be “forward-looking statements” within the meaning of the federal securities laws. These statements relate to anticipated future events, future results of operations and or future financial performance. In some cases, you can identify forward-looking statements by their use of terminology such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “future,” “intend,” “may,” “ought to,” “plan,” “possible,” “potentially,” “predicts,” “project,” “should,” “will,” “would,” negatives of such terms or other similar terms. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The forward-looking statements in this Quarterly Report on Form 10-Q include, without limitation, statements relating to:\n\n \n\n \n\n·\n\nour goals and strategies;\n\n \n\n \n\n \n\n \n\n·\n\nour future business development, results of operations and financial condition;\n\n \n\n \n\n \n\n \n\n·\n\nour estimates regarding expenses, future revenues, capital requirements and our need for additional financing;\n\n \n\n \n\n \n\n \n\n·\n\nour estimates regarding the market opportunity for our services;\n\n \n\n \n\n \n\n \n\n·\n\nthe impact of government laws and regulations;\n\n \n\n \n\n \n\n \n\n·\n\nour ability to recruit and retain qualified personnel;\n\n \n\n \n\n \n\n \n\n·\n\nour failure to comply with regulatory guidelines;\n\n \n\n \n\n \n\n \n\n·\n\nuncertainty in industry demand;\n\n \n\n \n\n \n\n \n\n·\n\ngeneral economic conditions and market conditions in the diagnostics, specialty chemicals and contract development and manufacturing (CDMO), and digital asset treasury strategies;\n\n \n\n \n\n \n\n \n\n·\n\nfuture sales of large blocks or our securities, which may adversely impact our share price; and\n\n \n\n \n\n \n\n \n\n·\n\ndepth of the trading market in our securities.\n\n \n\nThe preceding list is not intended to be an exhaustive list of all of our forward-looking statements. Forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties, including those described in Item 1A “Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and elsewhere in this Quarterly Report on Form 10-Q.\n\n \n\nYou should not unduly rely on any forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Quarterly Report on Form 10-Q to conform these statements to actual results or to changes in our expectations.\n\n \n\n \n\n3\n\n*Table of Contents*\n\n \n\n**PART I — FINANCIAL INFORMATION**"}